Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

Autor: Michiel Rienstra, Debra Marshall, William T. Abraham, Michel White, Ian A. Carroll, Sophia P. Huebler, Ryan Aleong, Dirk J. van Veldhuisen, Stephen B. Wilton, William H. Sauer, Stuart J. Connolly, Jonathan P. Piccini, Inder S. Anand, Christopher M. O'Connor, Jeff S. Healey, Christopher Dufton, Michael R. Bristow

Publikováno v: Heart rhythm O2, 3(1), 40-49

Background: Heart failure (HF) patients with atrial fibrillation (AF) often have conduction system disorders, which may be worsened by β-blocker therapy.Objective: In a post hoc analysis we examined the prevalence of bradycardia and its association

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c86dcdd227d41b4d3c403bd96061ea
https://doi.org/10.1016/j.hroo.2021.11.005

Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype

Autor: Jonathan P. Piccini, Christopher Dufton, Ian A. Carroll, Jeff S. Healey, William T. Abraham, Yaariv Khaykin, Ryan Aleong, Steven K. Krueger, William H. Sauer, Stephen B. Wilton, Michiel Rienstra, Dirk J. van Veldhuisen, Inder S. Anand, Michel White, A. John Camm, Paul D. Ziegler, Debra Marshall, Michael R. Bristow, Stuart J. Connolly, F Ayala-Paredes, A Bakbak, ML Bernier, DH Birnie, B Coutu, E Crystal, MW Deyell, KM Dyrda, MC Hartleib, ZW Laksman, P Leong-Sit, CA Morillo, AS Pandey, F Philippon, S Vizel, P Andréka, Z Csanadi, GZ Duray, T Forster, G Kerkovits, B Merkely, AC Nagy, T Simor, D Czarnecka, JD Kasprzak, WJ Musial, G Raczak, J Szachniewicz, JK Wranicz, S Apostolović, S Hinić, V Miloradović, D Simić, GJ Milhous, A Oomen, TJ Romer, LM van Vijk, PB Adamson, JD Allred, N Amjadi, MM Bahu, AJ Bank, AE Berman, MA Bernabei, RS Bhagwat, L Borgatta, AJ Buda, RT Cole, JL Collier, SJ Compton, O Costantini, MR Costanzo, IM Dauber, MP Donahue, I Dor, GF Egnacyzk, EJ Eichhorn, CC Eiswirth, S Emani, GA Ewald, RC Forde-McLean, MD Gelernt, DE Haines, CA Henrikson, JM Herre, B Herweg, L Ilkhanoff, LR Jackson, A Lala, R Lo, B London, BD Lowes, JA Mackall, V Malhotra, FA McGrew, S Murali, A Natale, KR Nilsson, J Okolo, MV Perez, RS Phang, R Ranjan, MY Rashtian, MJ Ross, SM Samii, T Shinn, MB Shoemaker, SA Strickberger, VN Tholakanahalli, A Tzur, PJ Wang, LT Younis

Publikováno v: Circulation. Arrhythmia and Electrophysiology, 14(8):009591. LIPPINCOTT WILLIAMS & WILKINS

Background: Bucindolol is a genetically targeted β-blocker/mild vasodilator with the unique pharmacological properties of sympatholysis and ADRB1 Arg389 receptor inverse agonism. In the GENETIC-AF trial (Genotype-Directed Comparative Effectiveness T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b3b46d4e71ba0e2188b0ff7e480073
https://research.rug.nl/en/publications/e4da658b-c78f-4c9f-a6ea-3c34cd1b9426

Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population

Autor: Béla Merkely, William T. Abraham, Michael R. Bristow, Laura L. Emery, Dirk J. van Veldhuisen, Michel White, Ian A. Carroll, Michiel Rienstra, William H. Sauer, Ryan G. Aleong, Leonard Ilkhanoff, Paul D. Ziegler, Jeff S. Healey, Christopher Dufton, Jonathan P. Piccini, Gordon Davis, Inder S. Anand, Yaariv Khaykin, Debra Marshall, Stuart J. Connolly, David P. Kao, Jerzy Krzysztof Wranicz, Vladimir Miloradovic, Steven K. Krueger, Stephen B. Wilton, Genetic-Af Trial Investigators, Felix Ayala-Paredes

Publikováno v: JACC: Heart Failure. 7:586-598

Objectives The purpose of this study was to compare the effectiveness of bucindolol with that of metoprolol succinate for the maintenance of sinus rhythm in a genetically defined heart failure (HF) population with atrial fibrillation (AF). Background

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d876e7717a82a56d38cf2101928024f
https://doi.org/10.1016/j.jchf.2019.04.004

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial

Autor: William H. Sauer, Hussein R. Al-Khalidi, Dirk J. van Veldhuisen, Gordon Davis, Richard Clark, William T. Abraham, Patricia Dignacco, Stephen B. Wilton, Christopher Dufton, Ryan G. Aleong, Benjamin A. Steinberg, Debra Marshall, Michael R. Bristow, Laura L. Emery, Stuart J. Connolly, Michel White, Jonathan P. Piccini, Inder S. Anand, Jeff S. Healey

Publikováno v: American Heart Journal, 199, 51-58. MOSBY-ELSEVIER

Background Few therapies are available for the safe and effective treatment of atrial fibrillation (AF) in patients with heart failure. Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d164044278b9a2064489078877018f8
https://research.rug.nl/en/publications/b8f34bcf-6be6-4acc-80b3-4d767404c8c2

ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension

Autor: Jeremy Feldman, Michael A. Mathier, Martine Allard, David B. Badesch, Adaani E. Frost, Anne Keogh, Darrin Despain, Michael D. McGoon, Lewis J. Rubin, Christopher Dufton, Shelley Shapiro, Harrison W. Farber, Ronald J. Oudiz

Publikováno v: Cardiovascular Therapeutics. 30:93-99

SUMMARY Introduction: Ambrisentan is an oral, once daily, endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension (PAH). Previous studies of ambrisentan were limited to patients with Group 1 PAH and often excluded pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bacb54e13681b7ec6bcfbf266f984160
https://doi.org/10.1111/j.1755-5922.2011.00279.x